

TAKHZYRO[®] PATIENT INFORMATION BOOKLET



You have been diagnosed with HAE and your physician has determined that you are an appropriate candidate to receive TAKHZYRO.

TAKHZYRO is a medicine that is used to prevent attacks of hereditary angioedema (HAE) in adults and adolescents (12 years and older). TAKHZYRO should not be used to treat an acute HAE attack. In the event of an acute attack, seek medical attention.

This booklet will not tell you everything about TAKHZYRO. Contact your doctor if you have any questions about this product. Be sure to follow your healthcare professional's instructions.

Do not inject yourself or someone else until you have been trained by your healthcare professional.



About

Mechanism
of Action

Dosing &
Administration

IFU

Side
Effects

OnePath[®]
Program

More Info

TAKHZYRO[®]
lanadelumab injection

WHAT IS HAE?

HAE is a rare genetic disorder that occurs in about 1 in 10,000 to 1 in 50,000 people worldwide.

The clinical course of HAE attacks is unpredictable.

HAE is characterized by episodes of swelling (edema attacks) in different areas of the skin or the internal organs.

- Edema of the skin occurs mainly in the face (e.g., lips, eyelids), although the extremities and genitals are also often affected.
- Edema of the mucous membranes affects the larynx, nose, or tongue.

WHAT IS TAKHZYRO USED FOR?

TAKHZYRO is a medicine that is used to prevent attacks of hereditary angioedema (HAE) in adults and adolescents (12 years and older). This is also known as prophylaxis.

Prophylaxis refers to the ongoing routine prevention of HAE attacks.

Prophylaxis does not eliminate the risk completely. You may still have HAE attacks. You and your healthcare team should make a plan to treat attacks on demand despite being on prophylactic therapy.



About

Mechanism
of Action

Dosing &
Administration

IFU

Side
Effects

OnePath®
Program


More Info

TAKHZYRO[®]
lanadelumab injection

HOW DOES TAKHZYRO WORK?

In HAE, uncontrolled production of a substance called plasma kallikrein occurs. This leads to the release of too much bradykinin in your bloodstream. Too much bradykinin leads to symptoms like swelling and pain (HAE attack).

TAKHZYRO is a type of protein that blocks the activity of plasma kallikrein. This helps to limit the production of bradykinin in your bloodstream and can prevent the swelling associated with HAE.



About	Mechanism of Action	Dosing & Administration	IFU	Side Effects	OnePath® Program	More Info
-------	---------------------	-------------------------	-----	--------------	------------------	-----------

DOSAGE AND ADMINISTRATION

What is the dosage of TAKHZYRO?

TAKHZYRO is a ready-to-use solution for injection under the skin (subcutaneous injection). It is supplied in a single-use prefilled syringe at a dosage of 300 mg/2 mL solution.

Your healthcare professional will prescribe the dose that you should take and how often you should take it.

What should I do if I miss a dose?

If you miss a dose of TAKHZYRO you should take your dose as soon as possible, ensuring at least 10 days between doses – do not take your missed dose at the same time as your next scheduled dose. If you are not sure when to take TAKHZYRO after a missed dose, ask your healthcare professional.

What should I do if I take too much TAKHZYRO?

If you think you have taken too much TAKHZYRO, contact your healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.



TAKHZYRO TIPS:

- Take your TAKHZYRO as prescribed
- Take TAKHZYRO on a day when you do an activity at a specified time to help you remember, for example, when putting out the recycling
- Mark your calendar or set a reminder for your next dose
- Ask a family member or friend to check in with you and help you stay on schedule



About

Mechanism
of Action

Dosing &
Administration

IFU

Side
Effects

OnePath®
Program

More Info

TAKHZYRO®
lanadelumab injection

TAKHZYRO administration


Do not inject yourself or someone else until you have been trained by your healthcare professional.

The administration of TAKHZYRO can be summarized as follows:

1. Prepare for your injection
2. Select and prepare injection site
3. Inject TAKHZYRO

Be sure that you read, understand, and follow the step-by-step instructions for injecting TAKHZYRO. A healthcare professional will show you how to prepare and inject TAKHZYRO properly before you use it for the first time. Contact your healthcare professional if you have any questions. Your OnePath® Care Manager will contact you to set up the injection training.

You can also find detailed instructions by visiting www.takhzyro.ca



About

Mechanism
of Action

Dosing &
Administration

IFU

Side
Effects

OnePath®
Program

More Info

TAKHZYRO®
lanadelumab injection

BEFORE TAKING TAKHZYRO...

Do not use TAKHZYRO if you:

- Are allergic to any ingredients in TAKHZYRO.
- Are pregnant or planning to become pregnant. It is not known if TAKHZYRO can harm your unborn baby.
- Are breastfeeding or plan to breastfeed. It is not known if TAKHZYRO passes into your milk and if it can harm your baby.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you use TAKHZYRO. Talk about any health conditions or problems you may have.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements, or alternative medicines.

- You should always follow the specific instructions given by your healthcare professional. The steps listed in this booklet are general guidelines for using TAKHZYRO. If you are unsure of the steps, contact your healthcare professional before using TAKHZYRO.



About

Mechanism
of Action

Dosing &
Administration

IFU

Side
Effects

OnePath®
Program

More Info

TAKHZYRO®
lanadelumab injection

INSTRUCTIONS FOR USE


Preparation:

- Collect all supplies listed below to prepare and give your injection.
- Inspect the supplies for damage. Do not use if they appear damaged.

You can also find detailed instructions for use by visiting www.takhzyro.ca

TAKHZYRO is a solution for injection under the skin (subcutaneous injection). It is supplied in a single-use prefilled syringe at a dosage of 300 mg/2 mL solution.

Parts of your TAKHZYRO prefilled syringe before use:



About	Mechanism of Action	Dosing & Administration	IFU	Side Effects	OnePath® Program	More Info
-------	---------------------	-------------------------	-----	--------------	------------------	-----------


STEP 1: Prepare for your injection



Alcohol swab




Cotton ball/gauze pad



Adhesive bandage



Sharps container



- a** Gather an alcohol swab, cotton ball/gauze pad, adhesive bandage and sharps disposal container and place them on a clean, flat, surface in a well-lit area. These supplies are not included in the TAKHZYRO packaging.
- b** Remove TAKHZYRO from the refrigerator, open the carton box, and remove the TAKHZYRO prefilled syringe from the tray.
 - **Before you prepare your injection, allow the prefilled syringe to come to room temperature for at least 15 minutes.**
 - Your medicine is sensitive to warm temperatures. **Do not** use external heat sources such as hot water to warm your TAKHZYRO prefilled syringe.
 - **Do not** remove the needle cap until you are ready to inject.
- c** Wash your hands with soap and water. Dry your hands completely.
- d** Check the **expiration date** on the label.
Do not use the TAKHZYRO prefilled syringe if the expiration date has passed.
- e** Visually inspect the TAKHZYRO prefilled syringe for any damage and make sure the medicine is colourless to slightly yellow.
 - Do not use the product if the syringe is damaged (e.g., cracked syringe).
 - Do not administer if the medicine is discoloured, cloudy, or has flakes or particles in it.
 - You might see air bubbles in the TAKHZYRO prefilled syringe. This is normal and will not affect your dose.



About

Mechanism
of Action

Dosing &
Administration

IFU


Side
Effects

OnePath®
Program


More Info

TAKHZYRO®
lanadelumab injection

STEP 2: Select and prepare injection site



- a** TAKHZYRO should be injected into your stomach (abdomen) or thigh. If given by a caregiver, TAKHZYRO may also be injected in the upper arm.
- It is important to rotate injection sites to keep skin healthy. Each new injection should be given at least 2 in (5cm) from the last site you used.
 - **Do not** inject into an area of your body where the skin is irritated, reddened, bruised, or infected.
 - The area you choose for injection should be at least 2 in (5 cm) away from any scars or your belly button (navel).
- b** Clean the injection site with an alcohol swab and allow it to dry.
- **Do not** fan or blow on the clean site.
 - **Do not** touch this area again before giving your injection.



- c** Remove the needle cap from the TAKHZYRO prefilled syringe. Gently pull the needle cap straight off with one hand and firmly hold the middle of the TAKHZYRO prefilled syringe with the other hand. Throw away the needle cap.
- **Do not** recap your TAKHZYRO prefilled syringe.
 - **Do not** use the TAKHZYRO prefilled syringe if it has been dropped without the needle cap on or if the needle looks damaged or bent.
 - **Do not** touch the needle or allow the needle to touch anything.



About

Mechanism
of Action

Dosing &
Administration

IFU


Side
Effects

OnePath®
Program


More Info

TAKHZYRO®
lanadelumab injection


STEP 3: Inject TAKHZYRO



- a Grip the TAKHZYRO prefilled syringe in one hand like a pencil. Avoid touching the needle or pushing on the plunger.
- b With your other hand, gently pinch a 1-inch (2.5 cm) fold of skin at the cleaned injection site.



- c Using a quick dart-like motion, insert the needle. Make sure to keep the needle in place.
- d **Slowly push** the plunger until all of the liquid is injected and the syringe is empty, then gently let go of your skin.



- e Slowly withdraw the needle while maintaining the syringe at the same angle.
- f Press a cotton ball or gauze pad over the injection site if needed and hold for 10 seconds.
 - **Do not** rub the injection site. You may have minor bleeding. This is normal.
 - Cover the injection site with an adhesive bandage if needed.



- g Throw away (dispose of) your used TAKHZYRO prefilled syringe.
 - **Do not** touch the needle.
 - To avoid a needle-stick injury, **do not** recap the needle.
 - Put your used TAKHZYRO prefilled syringes in a sharps disposal container right away after use. **Do not** reuse the TAKHZYRO prefilled syringe and any of your injection supplies.

There may be provincial and local laws about the right way to throw away used syringes. Ask your healthcare professional how to throw away used syringes.



About

Mechanism
of Action

Dosing &
Administration

IFU

Side
Effects

OnePath®
Program

More Info

TAKHZYRO®
lanadelumab injection

Possible side effects from using TAKHZYRO

These are not all the possible side effects that you may feel when taking TAKHZYRO. If you experience any side effects not listed here, tell your healthcare professional.

Stop taking TAKHZYRO and tell a healthcare professional immediately if you experience any of the following symptoms of an allergic reaction after taking this medicine. Although they are rare, the symptoms can be severe.

- Sudden wheeziness
- Difficulty in breathing
- Swelling of eyelids, face, or lips
- Rash or itching (especially affecting the whole body)
- Tight feeling in your chest

The most common side effect seen with TAKHZYRO was injection site reactions including pain, redness, and bruising followed by hypersensitivity, myalgia (muscle pain), dizziness, and raised skin rash/skin redness.

Do not drive or operate machinery if you feel dizzy after using TAKHZYRO.

If you have a troublesome symptom or side effect that is not listed here or that becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

Storage

- Store in a refrigerator (2–8°C). Do not freeze. Do not shake.
- Prefilled syringes removed from refrigeration should be stored at room temperature (below 25°C) and used within 14 days. Do not return prefilled syringes to refrigerated storage after storage at room temperature.
- Keep prefilled syringes in the original carton in order to protect the medicine from light.
- Dispose of any unused medicine.
- Keep out of reach and sight of children under 12.



About

Mechanism
of Action

Dosing &
Administration

IFU

Side
Effects

OnePath®
Program

More Info

TAKHZYRO®
lanadelumab injection


A PATIENT'S JOURNEY THROUGH THE OnePath[®] PROGRAM

Once enrolled we can help support you on your treatment journey by:

- Navigating reimbursement (if applicable)
- Educating you about your medication
- Providing you with ongoing support

Your personalized OnePath[®] Care Manager will:

- Assist you in understanding your insurance coverage
- Work with you and your physician to confirm your treatment start date
- Coordinate the ordering of your treatment and any additional supplies



About

Mechanism of Action

Dosing & Administration

IFU

Side Effects

OnePath[®] Program

More Info

For more information about TAKHZYRO

If you want more information about TAKHZYRO or you want to know more about self-administration:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes Patient Medication Information by visiting the manufacturer's website at www.takeda.com/en-ca/takhzyropm or by calling **1-800-268-2772**
- Visit www.takhzyro.ca

If you have any questions at any point in time, contact the OnePath Patient Support Program by calling the toll-free telephone number **1-844-MY1-PATH (1-844-691-7284)**, or emailing support@onepathprogram.ca

Additional support

HAE Canada Patient Organization

- HAE Canada is a patient group formed in 2010 to work with physicians, nurses, and other healthcare-related professionals to create a better life for HAE patients living in Canada. All HAE patients in Canada are encouraged to join this group. There is no membership fee and you will find many helpful resources. For more information, visit www.haecanada.org.

L'Angio-oedème héréditaire du Québec (AOHQ)

- The purpose of L'Angio-oedème héréditaire du Québec is to contribute to improving the health and quality of life of people with HAE.

Canadian Hereditary Angioedema Network (CHAEN)

- If you are looking for a HAE physician and/or clinic, please visit www.chaen-rcah.ca/patient-resources/.



About

Mechanism
of Action

Dosing &
Administration

IFU


Side
Effects

OnePath®
Program


More Info

TAKHZYRO[®]
lanadelumab injection



The images depicted contain models and are being used for illustrative purposes only.
TAKHZYRO is a registered trademark of Dyax Corp.
ONEPATH and  are trademarks or registered trademarks of Shire Human Genetic Therapies, Inc.



Takeda Canada Inc.
www.takeda.com/en-ca
TAKEDA and  are registered trademarks of Takeda Pharmaceutical Company Limited, used under license.
© 2024 Takeda Pharmaceutical Company Limited. All rights reserved.
NPRMCDA/CA/TAKH/0009



TAKHZYRO[®]
lanadelumab injection



About	Mechanism of Action	Dosing & Administration	IFU	Side Effects	OnePath [®] Program	More info
-------	---------------------	-------------------------	-----	--------------	------------------------------	-----------